Yale University Sponsored Projects — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$169,047	15
2024	Research	$157,315	12
2023	Research	$7,115	6
2022	Research	$76,793	23
2021	Research	$150,335	27
2020	Research	$128,906	31
2019	Research	$336,953	35

Breakdown

Who paid Research payments · program years 2019–2025

Sanofi US Services Inc. $742,444 77 payments
Genzyme Corporation $268,586 70 payments
Sanofi Pasteur Inc. $15,433 2 payments

Studies the money was for Research payments · program years 2019–2025

An Exploratory, Randomized, Double-blind, Placebo-controlled, Parallel Arm Trial of the Safety and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients Hospitalized With Worsen $226,302 10 payments
A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) $122,447 12 payments
A Phase 3, Multicenter, Multinational, Randomized, Double-blind, Double-dummy, Active-comparator Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (GD3) Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ERT) $119,445 21 payments
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc) $110,947 2 payments
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $93,569 2 payments
A First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Antitumor Activity of SAR408701 in Patients With Advanced Solid Tumors $75,523 13 payments
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects with Diffuse Cutaneous Systemic Sclerosis $66,609 2 payments
Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) $32,303 11 payments
Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPK $20,417 10 payments
An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary $17,588 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.